Journal article
Tumor Protection Following Vaccination With Low Doses of Lentivirally Transduced DCs Expressing the Self-antigen erbB2
Abstract
Gene therapy strategies may accelerate the development of prophylactic immunotherapy against cancer. We synthesized a lentiviral (LV) vector encoding a kinase-deficient form of erbB2 (erbB2tr) to transduce murine dendritic cells (DCs) efficiently. Murine erbB2 models a clinically relevant tumor-associated self-antigen; its human homolog (HER-2/neu) is overexpressed in breast cancer and in 80% of metastatic prostate cancers. Following one …
Authors
Mossoba ME; Walia JS; Rasaiah VI; Buxhoeveden N; Head R; Ying C; Foley JE; Bramson JL; Fowler DH; Medin JA
Journal
Molecular Therapy, Vol. 16, No. 3, pp. 607–617
Publisher
Elsevier
Publication Date
March 2008
DOI
10.1038/sj.mt.6300390
ISSN
1525-0016
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCancer VaccinesCell Line, TumorCytokinesDendritic CellsFemaleFlow CytometryGenetic TherapyGreen Fluorescent ProteinsImmunotherapy, AdoptiveKiller Cells, NaturalLentivirusMaleMiceMice, Inbred BALB CMice, Inbred C57BLProstatic NeoplasmsReceptor, ErbB-2Recombinant Fusion ProteinsSpleenTransduction, GeneticVaccination